New generations of antibody-based therapeutics, designed with structural mutations, have posed a challenge to traditional enzyme technologies. These therapeutic antibodies, while offering enhanced efficacy and stability, could not be digested with legacy FabRICATOR® (IdeS), preventing researchers from utilizing the efficient middle-level workflows previously enabled by the enzyme.

FabRICATOR® Xtra is an innovative solution to this challenge. With its ability to precisely and efficiently digest novel engineered antibody formats, Genovis is once again advancing analytical workflows for developers of future therapeutics antibodies. The new enzyme offers the same high level of accuracy and speed that users have come to expect from FabRICATOR®, ensuring that it can seamlessly integrate into existing workflows while supporting the development of future antibody-based therapies.

“With FabRICATOR® Xtra, we’re excited to offer a solution to our customers working at the forefront of antibody-based therapeutic innovation. Our next-generation enzyme supports more complex and mutated antibody formats, giving researchers the tools they need to continue developing the therapies of tomorrow”, said Fredrik Olsson, CEO at Genovis.

FabRICATOR® Xtra builds upon the success of its predecessor by maintaining the same precision, accuracy, and efficiency, while extending its utility to novel formats. Genovis remains committed to supporting the biopharmaceutical industry with innovative, high-performance tools that address the demands of modern therapeutic development.

For more information on FabRICATOR® Xtra please visit: https://www.genovis.com/smartenzymes/antibody-digestion/fabricator-xtra/